Grafa News and Videos — Page 600

Stellar’s cross-border payment network continues to gain attention as its anchor system links blockchain settlement with real-world remittance corridors across several major markets.

MBX Biosciences (NASDAQ:MBX) announced detailed results from its 12-week Avail Phase 2 clinical trial and new one-year data from an ongoing open-label extension study evaluating its investigational endocrine therapy, canvuparatide.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported new clinical trial data and supportive real-world evidence evaluating its hereditary angioedema (HAE) portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Annual Meeting in Istanbul, Turkey.

Kymera Therapeutics (NASDAQ:KYMR) reported positive findings from its Phase 1 clinical trial evaluating KT-621, a first-in-class oral small molecule STAT6 degrader, in healthy Japanese adults.

Rocket Pharmaceuticals (NASDAQ:RCKT) completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), generating $180 million in gross, non-dilutive cash proceeds.

United Community Banks (NYSE:UCB) entered into a definitive agreement to sell its specialty equipment finance business, comprising Navitas Credit Corp. and NLFC Reinsurance Corp., to investment funds managed by private equity firm Wafra.

Medallion Bank (NASDAQ:MBNKO), a wholly owned subsidiary of Medallion Financial Corp. (NASDAQ:MFIN), announced an orderly leadership succession plan under which long-serving Chief Executive Officer Donald Poulton will retire at mid-year.

Vertiv Holdings (NYSE:VRT) has finalized its acquisition of ThermoKey, a specialized European manufacturer of heat-rejection and heat-exchange systems, directly expanding its critical digital infrastructure portfolio.

JinkoSolar Holding (NYSE:JKS) announced that its Board of Directors has declared a standalone cash dividend, accelerating its structural capital return initiatives.

ArrowMark Financial (NASDAQ:BANX) declared its monthly cash distribution for June 2026, sustaining its consistent capital return schedule on the back of resilient quarterly earnings.